Abemaciclib in HR+/HER2– Advanced Breast Cancer Well-Tolerated With Manageable Adverse Effects
Safety analysis of abemaciclib found the drug is generally well-tolerated, with most common adverse effects were low-grade and reversible on treatment discontinuation.